Patented, a Molecule that Opens the Door to Develop New Drugs Against Immune Rejection
News Aug 01, 2013
The results of the study that describes this molecular mechanism have been published in the journal Molecular Cell Research.
Patients undergoing a transplant need nowadays a treatment for life to stop the immune response generated by the rejection of his body towards a foreign organism. Drugs that are used currently, cyclosporin A and FK506, inhibit calcineurin, which is the enzyme that activates the immune response. The problem is that their mechanism of action is to stop all the other tracks that activate this enzyme causing numerous side effects.
“The purpose of the investigation is to develop new and more specific drugs, that inhibit only the immune response triggered by the calcineurin and not all of its other functions”, explained the researcher Mercedes Pérez.
In previous studies, the team of Perez had already described a peptide of the protein family RCAN able to join the calcineurin and to inhibit specifically the activation of the immune response. In this work, the researchers of the IDIBELL have modified this peptide and further discovered that when this peptide is phosphorylated by protein CK2 (phosphorylation is a regulatory mechanism of proteins that involves the addition of a phosphate group) increases its immunosuppressive power.
“We have patented this phosphorylated peptide that in addition to its potential as an immunosuppressor will allow us to search for mimetic molecules which do the same function but are more stable, allowing us to be able to translate to the clinic”, explained the researcher.
The study was conducted in collaboration with the University of Barcelona, the Autonomous University of Barcelona and the Barcelona Biomedical Research Park (PRBB).
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Toothpaste Ingredient Could Help Fight Drug-Resistant MalariaNews
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE